PharmaEssentia Corporation
6446
株式のランク
#1448
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
株価
$35.96
時価総額
$14.87B
変化（1日）
-0.85%
変化（1年）
138.77%
国
TW
取引 PharmaEssentia Corporation (6446)
カテゴリー
Healthcare
PharmaEssentia Corporation（6446）の株価履歴
終値の最高値: $37.51 （2026-10-01）
終値の最安値: $4.95 （2014-03-01）
終値の最安値: $4.95 （2014-03-01）
PharmaEssentia Corporation の株価履歴（2014 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 78.21% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $162.56 | 21.57% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $224.93 | 31.35% |
CH
|
|
| $18.43 | -4.03% |
IN
|
